Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014–2018

Rachel E. Barenie (), Joshua J. Gagne, Aaron S. Kesselheim, Ajinkya Pawar, Angela Tong, Jing Luo and Brian T. Bateman
Additional contact information
Rachel E. Barenie: Brigham and Women’s Hospital and Harvard Medical School
Joshua J. Gagne: Brigham and Women’s Hospital and Harvard Medical School
Aaron S. Kesselheim: Brigham and Women’s Hospital and Harvard Medical School
Ajinkya Pawar: Brigham and Women’s Hospital and Harvard Medical School
Angela Tong: Brigham and Women’s Hospital and Harvard Medical School
Jing Luo: Brigham and Women’s Hospital and Harvard Medical School
Brian T. Bateman: Brigham and Women’s Hospital and Harvard Medical School

Drug Safety, 2020, vol. 43, issue 7, No 9, 669-675

Abstract: Abstract Introduction Clinical practice guidelines recommend co-prescribing naloxone to patients at high risk of opioid overdose, but few such patients receive naloxone. High costs of naloxone may contribute to limited dispensing. Objective The aim of this study was to evaluate rates and costs of dispensing naloxone to patients receiving opioid prescriptions and at high risk for opioid overdose. Methods Using claims data from a large US commercial insurance company, we conducted a retrospective cohort study of new opioid initiators between January 2014 and December 2018. We identified patients at high risk for overdose defined as a diagnosis of opioid use disorder, prior overdose, an opioid prescription of ≥ 50 mg morphine equivalents/day for ≥ 90 days, and/or concurrent benzodiazepine prescriptions. Results Among 5,292,098 new opioid initiators, 616,444 (12%) met criteria for high risk of overdose during follow-up, and, of those, 3096 (0.5%) were dispensed naloxone. The average copayment was US$24.83 for naloxone (standard deviation [SD] 67.66) versus US$9.74 for the index opioid (SD 19.75). The average deductible was US$6.18 for naloxone (SD 27.32) versus US$3.74 for the index opioid (SD 25.56), with 94% and 88% having deductibles of US$0 for their naloxone and opioid prescriptions, respectively. The average out-of-pocket cost was US$31.01 for naloxone (SD 73.64) versus US$13.48 for the index opioid (SD 34.95). Conclusions Rates of dispensing naloxone to high risk patients were extremely low, and prescription costs varied greatly. Since improving naloxone’s affordability may increase access, whether naloxone’s high cost is associated with low dispensing rates should be evaluated.

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-020-00923-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:43:y:2020:i:7:d:10.1007_s40264-020-00923-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-020-00923-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().